SARABETH CLARK: Open Payments
NPI 1720863665 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$875 in 42 payments from 16 companies in 2025. Trend: 2023 $18 · 2024 $259 · 2025 $875
Food & beverage: $875
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $333 |
| AstraZeneca Pharmaceuticals LP | 5 | $100 |
| Medtronic, Inc. | 1 | $93 |
| Phathom Pharmaceuticals, Inc. | 4 | $70 |
| Novo Nordisk Inc | 3 | $55 |
| TOLMAR, INC. | 2 | $34 |
| Lilly USA, LLC | 2 | $31 |
| Lundbeck LLC | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| PFIZER INC. | 1 | $21 |
Products named: QULIPTA, UBRELVY, INTELLIS ADAPTIVESTIM, BREZTRI, VOQUEZNA, VRAYLAR, LINZESS, JATENZO.
Industry payments across MS — which companies pay providers there.
